UroOncology Review
Dr. Joseph Chin Uro-Oncology Spring Review May 25, 2024
The 28th Annual Urologic Oncology Review will take place on May 25, 2024 at the Ivey Spencer Leadership Centre, 551 Windermere Road, London, ON, N5X 2T1
This year, we will be joining the JK Wyatt Urology Residents Research Day, that will happen on May 24, 2024 at the same venue.
Our guest professor, Dr. Stephen Freedland, will be joining us from Cedars-Sinai in California. His recent lead of the EMBARK clinical trial (Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer - PubMed (nih.gov)) has significantly advanced our understanding and treatment of prostate cancer. Please see his brief biography below.
We are also fortunate this year to have Dr. Joseph Chin return to the stage to regale us on everything he has been up to (both academic and non-academic pursuits!) post-retirement.
The rest of the agenda will provide participants with a state-of-the-art talks given by our illustrious faculty. Please see the agenda below for further details.
We look forward to welcoming you to London for this great academic urology tradition.
Warm Regards,
Uro-Oncology Retreat Organizing Committee
To register: Please complete the registration form at the bottom of this page.
To book accommodations CLICK HERE (Ivey Spencer Leadership Centre, a Dolce by Wyndham | London, ON Hotels (wyndhamhotels.com)). Should you need any adjustments to the pre-set accommodations with the venue, please call the venue at 519-679-4546 (option 3).
Dr. Stephen Freedland Biography (Stephen Freedland Profile | Cedars-Sinai Medical Center)
Stephen Freedland, MD, is director of the Center for Integrated Research in Cancer and Lifestyle and associate director for Training and Education at the Samuel Oschin Comprehensive Cancer Institute. He is the Warschaw, Robertson, Law Families Chair in Prostate cancer and professor in the Department of Urology at Cedars-Sinai. Freedland's clinical expertise focuses on urological diseases, particularly benign prostatic hyperplasia and prostate cancer. His approach toward cancer prevention and awareness focuses on treating the whole patient, not just the disease, by combining traditional Western medicine with complementary holistic interventions. His research interests include urological diseases and the role of diet, lifestyle and obesity in prostate cancer development and progression, as well as prostate cancer among racial groups and risk stratification for men with prostate cancer. Freedland has published over 700 studies, and his research has appeared in the Journal of the American Medical Association, Journal of the National Cancer Institute, Journal of Clinical Oncology, Journal of Urology, Cancer Prevention Research, Cancer and BJUI, among others. Freedland is an active reviewer for more than 50 journals. He sits on the editorial board for Cancer Prevention Research, International Journal of Urology, Nature Reviews Urology, Asian Journal of Andrology, and serves as editor-emeritus for Prostate Cancer and Prostatic Diseases. Freedland earned his MD from the University of California, Davis. He completed a residency in urology at UCLA and a fellowship in urological oncology at Johns Hopkins. Before joining Cedars-Sinai, he was at Duke University, where he specialized in surgical oncology and urologic oncology, and served as an associate professor in the Division of Urology.
Agenda: TBD
